Previous 10 | Next 10 |
Speakers from Academia, Large Pharma Collaborations and Regulatory Agencies shared their real-world impact using modeling & simulation technology Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pha...
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will be presenting at Oppenheimer’s 31 st An...
The 23 businesses comprise 99% of the portfolio with the other 1% in cash, and the average total return over the Dow average for the 62-month test period is 36.07%. The objective of the portfolio is to create a balanced portfolio that is not income, not dividend growth, not bottom fis...
Computational Modeling, Human Liver Microphysiology Systems (MPS) and the MPS-Database Platforms to be Integrated for Safety Testing Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safet...
The following slide deck was published by Simulations Plus, Inc. in conjunction with this event. For further details see: Simulations Plus (SLP) Presents At MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference - Slideshow
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, and Will Frederick, chief financial officer, will be ho...
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has released version 9.8.1 of its flagship physiologically based biopharmaceutics (PB...
The modelling and simulation software market for drug discovery and development is niche and IP-intensive, with high barriers to entry. Simulations Plus has a good track record and strong balance sheet, providing opportunities for multiple pathways to growth. The insider sales by ...
Polen Capital is a global independently-owned growth equity boutique, led by an experienced team of investment professionals who are committed to preserving and growing the assets of our clients through. The Polen U.S. Small Company Growth Composite Portfolio returned 29.14%, gross of...
Extends reach of MonolixSuite™ to China’s growing pharmacology market Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today ann...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...